Pulse Biosciences (PLSE) EBT Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted EBT Margin of 5684.79% for Q2 2026, up 13.89% on a QoQ basis from 6601.52% in Q4 2025.

Analysis

Pulse Biosciences (PLSE) EBT Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences has reported EBT Margin for 4 years, with the latest figure at 5684.79% in Q2 2026.

On a quarterly basis, EBT Margin changed N/A year-over-year to 5684.79% in Q2 2026; TTM through Jun 2026 was 10284.95%, a N/A change from a year earlier, with the FY2025 full-year figure at 20779.71%, changed N/A from the prior year.
EBT Margin was 5684.79% for Q2 2026 at Pulse Biosciences, up from 6601.52% in the prior quarter.
The five-year high for EBT Margin was 102188.89% in Q4 2022, with the low at 22518.6% in Q3 2025.
Average EBT Margin over 3 years is 9804.72%, with a median of 5175.06% recorded in 2022.
The largest YoY upside for EBT Margin was 10401543 bps in 2022 against a maximum downside of 10401543 bps in 2022.
Over 3 years, EBT Margin stood at 102188.89% in 2022, then sank by 106 bps to 6601.52% in 2025, then climbed by 14 bps to 5684.79% in 2026.
The last three EBT Margin figures came in at 5684.79% (Q2 2026), 6601.52% (Q4 2025), and 22518.6% (Q3 2025), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	179.79 Bn	174.18 Bn	7.27 Bn	12.10%
2	Intuitive Surgical	127.69 Bn	122.47 Bn	1.96 Bn	36.46%
3	Medtronic	117.23 Bn	108.41 Bn	6.34 Bn	18.13%
4	Stryker	103.55 Bn	100.07 Bn	4.50 Bn	23.74%
5	Boston Scientific	63.24 Bn	62.70 Bn	3.85 Bn	19.48%
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn	29.86%
7	Alcon	32.83 Bn	31.37 Bn	1.68 Bn	-1.65%
8	Dexcom	32.30 Bn	30.35 Bn	830.00 Mn	24.27%
9	Steris	20.73 Bn	20.25 Bn	684.20 Mn	18.32%
10	Pulse Biosciences	3.76 Bn	3.76 Bn	161,000.00	-5,684.79%

Historic Data

Download Data